— Know what they know.
Not Investment Advice

ATHA NASDAQ

Athira Pharma, Inc.
1W: +0.8% 1M: +78.1% 3M: +80.2% 1Y: +37.6% 3Y: -75.4% 5Y: -97.8%
$6.75
Last traded 2025-12-31 — delisted
NASDAQ · Healthcare · Biotechnology · $26.6M mcap · 3M float · 34.63% daily turnover · Short 45% of daily vol

Balance Sheet Trends

Total Assets
$59M -63.3% ▼
5Y CAGR: +93.1%
Total Liabilities
$14M -53.6% ▼
5Y CAGR: -8.7%
Shareholders Equity
$45M -65.6% ▼
Cash & Investments
$51M -65.2% ▼
5Y CAGR: +90.3%
Total Debt
$1M -23.2% ▼
5Y CAGR: -4.8%
Net Debt
-$47M +46.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$61M$111M$96M$91M$48M
Short-Term Investments$124M$143M$104M$57M$3M
Cash & ST Investments$185M$254M$200M$147M$51M
Net Receivables$1M$2M$1M$2M$0
Inventory$0$0-$1M$0$0
Other Current Assets$0$0$7M$6M$4M
Total Current Assets$192M$261M$208M$155M$55M
Property, Plant & Equip.$4M$5M$5M$4M$3M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$84M$66M$45M$631K$631K
Other Non-Current Assets$132K$56K$475K$448K$55K
Total Non-Current Assets$87M$71M$51M$6M$4M
Total Assets$280M$332M$258M$160M$59M
— Liabilities —
Accounts Payable$1M$567K$3M$129K$319K
Short-Term Debt$0$0$0$0$414K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$2M$15M$24M$12M
Total Current Liabilities$4M$9M$21M$29M$13M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$876K$2M$2M$1M$803K
Total Liabilities$5M$11M$23M$30M$14M
— Equity —
Common Stock$3K$4K$4K$4K$4K
Retained Earnings-$41M-$96M-$192M-$309M-$406M
Accumulated OCI$33K-$388K-$2M-$349K$1K
Total Stockholders Equity$274M$321M$235M$130M$45M
Total Liabilities & Equity$280M$332M$258M$160M$59M
— Key Metrics —
Total Debt$1M$2M$2M$2M$1M
Net Debt-$60M-$109M-$94M-$89M-$47M
Total Investments$208M$209M$149M$57M$3M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms